{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:42:01Z","timestamp":1792449721356,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-08433-y","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T08:29:23Z","timestamp":1784795363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risperidone for children with attention-deficit\/hyperactivity disorder and severe behavioral dysregulation: a randomized placebo-controlled assessor-blinded trial"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8372-2911","authenticated-orcid":false,"given":"Ezatollah","family":"Abbasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-2290","authenticated-orcid":false,"given":"Alireza","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8834-4451","authenticated-orcid":false,"given":"Rana","family":"Eskandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"8433_CR1","doi-asserted-by":"crossref","unstructured":"Association AP. Diagnostic and statistical manual of mental disorders. American Psychiatric Association Publishing. 2022.","DOI":"10.1176\/appi.books.9780890425787"},{"issue":"1","key":"8433_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3928\/02793695-20221207-01","volume":"61","author":"F Ramos-Marcuse","year":"2023","unstructured":"Ramos-Marcuse F, Kverno K. Evidence-Based Use of Atypical Antipsychotics in the Care of Children and Adolescents. J Psychosoc Nurs Ment Health Serv. 2023;61(1):8\u201311.","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"issue":"10024","key":"8433_CR3","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(15)00238-X","volume":"387","author":"A Thapar","year":"2016","unstructured":"Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387(10024):1240\u201350.","journal-title":"Lancet"},{"issue":"5","key":"8433_CR4","doi-asserted-by":"publisher","first-page":"I","DOI":"10.1016\/j.jpeds.2009.01.018","volume":"154","author":"AF Arnsten","year":"2009","unstructured":"Arnsten AF. The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr. 2009;154(5):I.","journal-title":"J Pediatr"},{"issue":"11","key":"8433_CR5","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.3390\/biomedicines10112818","volume":"10","author":"RP Rajkumar","year":"2022","unstructured":"Rajkumar RP. Antipsychotics in the management of disruptive behavior disorders in children and adolescents: An update and critical review. Biomedicines. 2022;10(11):2818.","journal-title":"Biomedicines"},{"issue":"3","key":"8433_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1542\/peds.2010-0165","volume":"127","author":"K Larson","year":"2011","unstructured":"Larson K, Russ SA, Kahn RS, Halfon N. Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics. 2011;127(3):462\u201370.","journal-title":"Pediatrics"},{"issue":"3","key":"8433_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/jcpp.12036","volume":"54","author":"S Cortese","year":"2013","unstructured":"Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54(3):227\u201346.","journal-title":"J Child Psychol Psychiatry"},{"issue":"2","key":"8433_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40263-013-0130-6","volume":"28","author":"AC Childress","year":"2014","unstructured":"Childress AC, Sallee FR. Attention-deficit\/hyperactivity disorder with inadequate response to stimulants: approaches to management. CNS Drugs. 2014;28(2):121\u20139.","journal-title":"CNS Drugs"},{"issue":"5","key":"8433_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/DBP.0b013e3181e121bd","volume":"31","author":"DF Connor","year":"2010","unstructured":"Connor DF, Steeber J, McBurnett K. A review of attention-deficit\/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder. J Dev Behav Pediatr. 2010;31(5):427\u201340.","journal-title":"J Dev Behav Pediatr"},{"issue":"9","key":"8433_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1089\/cap.2018.0037","volume":"28","author":"ES Lee","year":"2018","unstructured":"Lee ES, Vidal C, Findling RL. A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics. J Child Adolesc Psychopharmacol. 2018;28(9):582\u2013605.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"8433_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1056\/NEJMoa013171","volume":"347","author":"JT McCracken","year":"2002","unstructured":"McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314\u201321.","journal-title":"N Engl J Med"},{"key":"8433_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.eurpsy.2019.08.013","volume":"62","author":"A Naguy","year":"2019","unstructured":"Naguy A, Hashem MS, AlKhadhar S. Atypical antipsychotics for Attention-Deficit\/Hyperactivity disorder-science, art, or fad? Eur Psychiatry. 2019;62:58\u20139.","journal-title":"Eur Psychiatry"},{"issue":"1","key":"8433_CR13","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.5812\/ijp.265","volume":"25","author":"F Arabgol","year":"2015","unstructured":"Arabgol F, Panaghi L, Nikzad V. Risperidone versus methylphenidate in treatment of preschool children with attention-deficit hyperactivity disorder. Iran J Pediatr. 2015;25(1):e265.","journal-title":"Iran J Pediatr"},{"key":"8433_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.psychres.2016.12.010","volume":"251","author":"L Jahangard","year":"2017","unstructured":"Jahangard L, Akbarian S, Haghighi M, Ahmadpanah M, Keshavarzi A, Bajoghli H, et al. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed\u2013Results from a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res. 2017;251:182\u201391.","journal-title":"Psychiatry Res"},{"issue":"9","key":"8433_CR15","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.19082\/2840","volume":"8","author":"F Riahi","year":"2016","unstructured":"Riahi F, Tashakori A, Abdi L. Comparison between the efficacies of Risperidone with Haloperidol in the treatment of attention-deficit hyperactivity disorder (ADHD) among preschoolers: a randomized double-blind clinical trial. Electron Physician. 2016;8(9):2840.","journal-title":"Electron Physician"},{"issue":"2","key":"8433_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/09540260801889179","volume":"20","author":"CU Correll","year":"2008","unstructured":"Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry. 2008;20(2):195\u2013201.","journal-title":"Int Rev Psychiatry"},{"key":"8433_CR17","doi-asserted-by":"crossref","unstructured":"DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale\u2014IV: Checklists, norms, and clinical interpretation. The Guilford Press. 1998.","DOI":"10.1037\/t00680-000"},{"issue":"4","key":"8433_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1023\/A:1022602400621","volume":"26","author":"CK Conners","year":"1998","unstructured":"Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners\u2019 Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257\u201368.","journal-title":"J Abnorm Child Psychol"},{"issue":"11","key":"8433_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/archpsyc.1983.01790100074010","volume":"40","author":"D Shaffer","year":"1983","unstructured":"Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A children\u2019s global assessment scale (CGAS). Arch Gen Psychiatry. 1983;40(11):1228\u201331.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"8433_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/1044546041649020","volume":"14","author":"MG Aman","year":"2004","unstructured":"Aman MG, Binder C, Turgay A. Risperidone effects in the presence\/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol. 2004;14(2):243\u201354.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"8433_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/070674371506000204","volume":"60","author":"DA Gorman","year":"2015","unstructured":"Gorman DA, Gardner DM, Murphy AL, Feldman M, B\u00e9langer SA, Steele MM, et al. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. Can J Psychiatry. 2015;60(2):62\u201376.","journal-title":"Can J Psychiatry"},{"issue":"2","key":"8433_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jaac.2019.12.009","volume":"60","author":"JC Blader","year":"2021","unstructured":"Blader JC, Pliszka SR, Kafantaris V, Foley CA, Carlson GA, Crowell JA, et al. Stepped treatment for attention-deficit\/hyperactivity disorder and aggressive behavior: a randomized, controlled trial of adjunctive risperidone, divalproex sodium, or placebo after stimulant medication optimization. J Am Acad Child Adolesc Psychiatry. 2021;60(2):236\u201351.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"8433_CR23","doi-asserted-by":"publisher","first-page":"174012","DOI":"10.1016\/j.pbb.2025.174012","volume":"251","author":"SF Collares","year":"2025","unstructured":"Collares SF, de \u00c1vila J\u00fanior AM, Martins TC, Rezende VHM, Romano-Silva MA, Santos RMS, et al. Systematic review and meta-analysis of weight gain and metabolic changes in children and adolescents using second-generation antipsychotics. Pharmacol Biochem Behav. 2025;251:174012.","journal-title":"Pharmacol Biochem Behav"},{"issue":"11","key":"8433_CR24","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","volume":"64","author":"RL Findling","year":"2003","unstructured":"Findling RL, Kusumakar V, Daneman D, Moshang T, De Smedt G, Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry. 2003;64(11):1362\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"8433_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1089\/cap.2024.0026","volume":"34","author":"S Sanyal","year":"2024","unstructured":"Sanyal S, Rowan PJ, Ochoa-Perez M, Calarge C, Aparasu R, Abughosh S, et al. Metabolic Monitoring for Children and Adolescents Prescribed Second-Generation Antipsychotics: A Qualitative Study with Child Psychiatrists. J Child Adolesc Psychopharmacol. 2024;34(8):359\u201365.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"8433_CR26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/chi.0b013e3180323354","volume":"46","author":"JL Armenteros","year":"2007","unstructured":"Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit\/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558\u201365.","journal-title":"J Am Acad Child Adolesc Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08433-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08433-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08433-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:21:19Z","timestamp":1792448479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08433-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8433"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08433-y","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"14 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Urmia University of Medical Sciences (IR.UMSU.REC.1402.388) and registered in the Iranian Clinical Trials Registry (IRCT20241228064189N1; registered on 2025-10-16- Retrospectively registered). All participants or their legal guardians provided written informed consent following the principles outlined in the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"808"}}